Myasthenia Gravis Patients See Moderate Improvement with Prograf, China Study Shows
Prograf (tacrolimus) moderately improves myasthenia gravis (MG) in patients with inadequate response to glucocorticoids (GCs), a new study from China…
José holds a BSc in Biochemistry and a PhD in Neuroscience from the University of Porto, in Portugal, and did post-docs in the U.S. and Canada (Weill Cornell Medicine and Western University, respectively) while still in academia. He joined Bionews in 2017 as a science writer and became a managing science editor in 2019. At Bionews, he has been able to cover the latest news related to multiple disease communities, while also doing interviews and covering several meetings. He is an author of 20 peer-reviewed papers and two book chapters. Topics of his research included the brain mechanisms implicated in Alzheimer’s disease, hypertension, and menopause. He also is a professor at the School of Health, Polytechnic of Porto.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Prograf (tacrolimus) moderately improves myasthenia gravis (MG) in patients with inadequate response to glucocorticoids (GCs), a new study from China…
ARGX-113, an investigational therapy for myasthenia gravis (MG), is progressing in a Phase 2 clinical trial (NCT02965573) that…
Get regular updates to your inbox.